Product Description
Mechanisms of Action: DNA Damager
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Nerviano Medical Sciences
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Hepatocellular Carcinoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2005-000731-26 |
2005-000731-26 | P2 |
Completed |
Hepatocellular Carcinoma |
2012-04-19 |
2022-03-12 |
Treatments |
|
2006-000798-31 |
2006-000798-31 | P2 |
Terminated |
Hepatocellular Carcinoma |
2007-05-16 |
2022-03-12 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
12/12/2024 |
News Article |
Elevation Oncology Licenses ADC Technology from Synaffix to Drive Pipeline Expansion |
|
12/04/2024 |
News Article |
Synaffix Licenses Metal-Free Click Chemistry Technology to Illumina for Next-Generation DNA Sequencing Applications |
|
10/12/2023 |
News Article |
Synaffix to Launch New ADC Technologies at the World ADC Conference in San Diego |
|
05/09/2019 |
News Article |
EnGeneIC Announces First Patients with Advanced-Stage Pancreatic Cancer Dosed in Phase 1/2a Clinical Study of Targeted Cytotoxic Immunotherapy |